推荐产品
等級
certified reference material
形狀
liquid
特點
Snap-N-Spike®/Snap-N-Shoot®
包裝
ampule of 1 mL
製造商／商標名
Cerilliant®
drug control
psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)
濃度
1.0 mg/mL in methanol
技術
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
應用
cannabis testing
forensics and toxicology
格式
single component solution
儲存溫度
2-8°C
SMILES 字串
OC1=CC(CCCCC)=CC2=C1C3C=C(CO)CCC3C(O2)(C)C
InChI
1S/C21H30O3/c1-4-5-6-7-14-11-18(23)20-16-10-15(13-22)8-9-17(16)21(2,3)24-19(20)12-14/h10-12,16-17,22-23H,4-9,13H2,1-3H3
InChI 密鑰
YCBKSSAWEUDACY-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
经认证的加标溶液®，适用于LC/MS或GC/MS应用，用于大麻素测试，尿液药物测试，临床毒理学或法医分析。11-羟基-Δ9-THC 是大麻主要精神活性成分（Δ9--四氢大麻酚 (Δ9-THC)）的主要氧化代谢物。
應用
该认证加标溶液®适用于通过 HPLC、GC/MS 或 LC-MS/MS 法进行 (±)-11-羟基-Δ9-THC 测定，从而用于法医分析、临床毒理学、尿液药物测试和大麻效力或杂质分析测试等应用。该认证标准物质（CRM）还可作如下用途：
- 使用超高效液相色谱（UHPLC）结合三重四极杆质谱法在液-液萃取后定量测定人血浆样品中的大麻二酚和 Δ9-四氢大麻酚，以及鉴定少量大麻素
- 基于液相色谱-串联质谱（LC-MS/MS）法在固相萃取（SPE）后测定口服液样品中的 10 种大麻素
- 通过气相色谱（GC）联合三重四极杆质谱仪分析血浆和尿液中 Δ9-四氢大麻酚（Δ9-THC）及其三种代谢物
- 开发基于固相萃取（SPE）的自动样品制备方法，以使用液相色谱-质谱法（LC-MS）测定血清、唾液和尿液中 ∆9--四氢大麻酚（THC）及其三种主要代谢物
- 通过大气压化学电离气相色谱-串联质谱法（APGC-MS/MS）同时测定人血清样品中的大麻素及其代谢物
特點和優勢
- 完全符合 ISO/IEC 17025 和 ISO 17034 认证
- 附综合分析证书（CoA），包括稳定性、均匀性、浓度准确性、不确定性和可追溯性数据
- 通过实时稳定性研究严格测试，以确保准确性和保质期
- 使用合格的精密天平进行重量准备，以确保最小不确定性
- 氩气环境下火焰密封，装入安瓿以便长期保存
- 提供方便的 DEA 豁免格式，以提高实验室效率
法律資訊
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Danger
危險分類
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
標靶器官
Eyes
儲存類別代碼
3 - Flammable liquids
水污染物質分類（WGK）
WGK 1
閃點（°F）
49.5 °F - closed cup
閃點（°C）
9.7 °C - closed cup
其他客户在看
Erin L Karschner et al.
Clinical chemistry, 57(1), 66-75 (2010-11-17)
Sativex(®), a cannabis extract oromucosal spray containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications
Erin L Karschner et al.
Analytical and bioanalytical chemistry, 397(2), 603-611 (2010-03-23)
A sensitive analytical method for simultaneous quantification of sub-nanogram concentrations of cannabidiol (CBD), Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) in plasma is presented for monitoring cannabinoid pharmacotherapy and illicit cannabis use. Analytes were extracted from 1 mL plasma by
Gisela Skopp et al.
Archiv fur Kriminologie, 229(5-6), 154-162 (2012-07-28)
The exculpatory statement that a positive THC finding in the blood is due to the consumption of hemp products or passive exposure to cannabis smoke has been disproved by the monitoring of hemp products and recent passive inhalation studies conducted
David A Gorelick et al.
Journal of clinical psychopharmacology, 31(5), 603-612 (2011-08-27)
Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ⁹-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis
J Röhrich et al.
Journal of analytical toxicology, 34(4), 196-203 (2010-05-15)
Cannabinoid concentrations in blood and urine after passive exposure to cannabis smoke under real-life conditions were investigated in this study. Eight healthy volunteers were exposed to cannabis smoke for 3 h in a well-attended coffee shop in Maastricht, Netherlands. An
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门